Human menstrual blood-derived stem cells as immunoregulatory therapy in COVID-19: A case report and review of the literature.
World J Clin Cases
; 9(7): 1705-1713, 2021 Mar 06.
Article
in English
| MEDLINE | ID: covidwho-1134506
ABSTRACT
BACKGROUND:
The coronavirus disease 2019 (COVID-19) caused by novel coronavirus 2019 in December 2019 has spread all around the globe and has caused a pandemic. There is still no current effective guidance on the clinical management of COVID-19. Mesenchymal stem cell therapy has been shown to be one of the therapeutic approaches to alleviate pneumonia and symptoms through their immunomo-dulatory effect in COVID-19 patients. CASESUMMARY:
We describe the first confirmed case of COVID-19 in Hangzhou to explore the role of human menstrual blood-derived stem cells (MenSCs) in the treatment of COVID-19. Moreover, we review the immunomodulation effect including non-specific and specific immune functions of MenSCs for the therapy of COVID-19.CONCLUSION:
MenSCs can be helpful to find a promising therapeutic approach for COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Case report
/
Prognostic study
Language:
English
Journal:
World J Clin Cases
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS